Vanda Pharmaceuticals shares are trading lower after the US Supreme Court reportedly declined to hear the company's case regarding the invalidation of patents for Hetlioz.
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharmaceuticals' shares dropped following the US Supreme Court's decision not to hear its case on the invalidation of patents for Hetlioz.
April 22, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vanda Pharmaceuticals' stock price is likely to experience a short-term decline due to the Supreme Court's refusal to hear its patent case for Hetlioz.
The refusal by the US Supreme Court to hear Vanda Pharmaceuticals' case regarding the invalidation of patents for Hetlioz directly impacts the company's potential revenue and market exclusivity for this product. This legal setback is likely to negatively affect investor confidence and the stock's value in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100